Skip to main content

MIRA Pharmaceuticals, Inc.

corporate_fare Company Profile

MIRA Pharmaceuticals, Inc.

MIRA·NASDAQ·Life Sciences·CIK 0001904286

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company focused on creating new oral medicines for neurological, neuropsychiatric, metabolic, and addiction-related conditions. The company has exclusive rights in the United States, Canada, and Mexico to three drug candidates: Ketamir-2, MIRA-55, and SKNY-1. These candidates are designed to address unmet medical needs in areas such as neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. Ketamir-2 is an oral NMDA receptor modulator that has completed a Phase 1 clinical trial in healthy volunteers, involving both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts. Preliminary safety data from this trial indicates no serious adverse events or dose-limiting toxicities, though the database is still blinded, and final analyses are ongoing. The company plans to start a Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026. MIRA-55 is a new oral, non-psychoactive cannabinoid analog currently in preclinical development for inflammatory pain and central nervous system conditions like anxiety and cognitive impairment. Preclinical studies have shown MIRA-55 has both pain-relieving and anti-inflammatory effects, comparable to morphine for pain relief, but without the central nervous system side effects seen with cannabinoids at tested doses. The company is moving MIRA-55 through IND-enabling development activities, aiming for an Investigational New Drug (IND) submission for inflammatory pain.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for MIRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for MIRA spans 10-Q, 8-K.

Recent high-impact activity:

  • MIRA Q3 10-Q: Cash Falls to $2.5M, Going-Concern Doubt and Nasdaq Bid-Price Notice
  • MIRA's Oral SKNY-1 Cuts Weight and Fat in Obese Mice, With Less Lean-Mass Loss Than Semaglutide
  • MIRA-55 Matches Celebrex for Pain Relief in 21-Day Chronic Pain Study
  • MIRA Advances Ketamir-2 to Phase 2a in CIPN After FDA Review
  • MIRA's Ketamir-2 Clears FDA Review, Heads to IRB for Phase 2a CIPN Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$10.44M
Diluted EPS
-$1.35
Op. Cash Flow
-$4.66M
Cash & Equivalents
$6.35M
Debt / Equity
0.00×
Shares Outstanding
41.94M sh
Source: 10-K · filed 2026-03-31 · accession 0001493152-26-014001

Short Interest & Short Volume

1.44 days to cover

FINRA reported short interest of 282,319 shares in MIRA as of the October 30, 2026 settlement, a 19.3% decrease from the prior period — about 1.4 days to cover at its recent average daily volume. On November 20, 2026, 21.4% of MIRA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)282,319 shares as of October 30, 2026
Change vs prior period▼ 19.3%
Days to cover1.44 at avg daily volume of 196,532
Daily short volume (FINRA facilities)21.4% of 315,625 shares on November 20, 2026
5-day average short volume23.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$0.297 +2.06% today
52-week range · as of 2026-11-16 $0.297 – $1.69
Market cap
$12.23M
Volume
570.1K (3.4× avg)
3-mo avg 167.8K
Live data · 2026-11-22 09:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MIRA - Latest Insights

MIRA
Nov 16, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.6283
Real-time Price: $0.297 info
Change: -$0.3313 (-53%) info
Market Cap: $12.228M info
MIRA
Oct 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5561
Real-time Price: $0.297 info
Change: -$0.2591 (-47%) info
Market Cap: $12.228M info
MIRA
Oct 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.681
Real-time Price: $0.297 info
Change: -$0.384 (-56%) info
Market Cap: $12.228M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.297 info
Change: -$0.4131 (-58%) info
Market Cap: $12.228M info
MIRA
Sep 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7101
Real-time Price: $0.297 info
Change: -$0.4131 (-58%) info
Market Cap: $12.228M info
MIRA
Aug 12, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.7387
Real-time Price: $0.297 info
Change: -$0.4417 (-60%) info
Market Cap: $12.228M info
MIRA
Aug 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7131
Real-time Price: $0.297 info
Change: -$0.4161 (-58%) info
Market Cap: $12.228M info
MIRA
Jul 31, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.792
Real-time Price: $0.297 info
Change: -$0.495 (-63%) info
Market Cap: $12.228M info
MIRA
Jul 10, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.297 info
Change: -$0.643 (-68%) info
Market Cap: $12.228M info
MIRA
Jul 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9376
Real-time Price: $0.297 info
Change: -$0.6406 (-68%) info
Market Cap: $12.228M info
MIRA
Jul 06, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.972
Real-time Price: $0.297 info
Change: -$0.675 (-69%) info
Market Cap: $12.228M info
MIRA
Jul 06, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9448
Real-time Price: $0.297 info
Change: -$0.6478 (-69%) info
Market Cap: $12.228M info
MIRA
Jun 25, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.297 info
Change: -$0.643 (-68%) info
Market Cap: $12.228M info
MIRA
Jun 17, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.949
Real-time Price: $0.297 info
Change: -$0.652 (-69%) info
Market Cap: $12.228M info
MIRA
Jun 08, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.297 info
Change: -$0.703 (-70%) info
Market Cap: $12.228M info
MIRA
Jun 04, 2026, 8:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $0.297 info
Change: -$0.743 (-71%) info
Market Cap: $12.228M info
MIRA
Jun 04, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.04
Real-time Price: $0.297 info
Change: -$0.743 (-71%) info
Market Cap: $12.228M info
MIRA
May 27, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.9999
Real-time Price: $0.297 info
Change: -$0.7029 (-70%) info
Market Cap: $12.228M info
MIRA
May 27, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $0.9999
Real-time Price: $0.297 info
Change: -$0.7029 (-70%) info
Market Cap: $12.228M info
MIRA
May 14, 2026, 3:03 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.979
Real-time Price: $0.297 info
Change: -$0.682 (-70%) info
Market Cap: $12.228M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets